ON THE FRONT LINE™ AGAINST INFLUENZA
DAVID ROSS
VP COMMERCIAL OPERATIONS
NORTH AMERICA

ON THE FRONT LINE

OUR SEQIRUS PURPOSE

Influenza can kill
We believe it shouldn't be that way
We exist to transform protection against influenza

ON THE FRONT LINE

PREPARING FOR A NEW NORMAL

In light of the current COVID-19 crisis, it is imperative that all the key stakeholders work together to ensure more people get immunized against influenza than ever before

We must rally around this effort

ON THE FRONT LINE

The seasonal influenza vaccine is the best way to reduce the incidence of influenza1 and is a vital public health tool in the battle against COVID-19.2

- Protect against the devastating impact influenza can have
- Minimize the risk of co-infection with COVID-19
- Minimize the burden on the healthcare system

ON THE FRONT LINE


ON THE FRONT LINE

COVID-19 has overwhelmed the healthcare system—a anticipated resurgence this fall/winter combined with seasonal influenza will result in an even tougher public health challenge.

Our immunization season will be like nothing we’ve ever seen before...

ON THE FRONT LINE

Influenza can kill
We believe it shouldn't be that way
We exist to transform protection against influenza

ON THE FRONT LINE

Early indicators suggest that healthcare providers and health authorities are planning for an increase in influenza immunization, but with uncertainty on how to best implement their campaigns.

Early indicators include:

- HCPs are planning for increasing demand
- More consumers are expected to seek vaccination
- Need for clear immunization objectives and guidelines
- Uncertainty about how to adjust for COVID-19 mitigation plans
- Beginnings define creative solutions

ON THE FRONT LINE

Market Trends
HCP Learnings
Australian Experience

- Increase in patient demand
- Increased awareness
- Immunization clinics

ON THE FRONT LINE

Need for a shared vision: we must come together as a community to ensure more people get immunized against influenza than ever before

Critical success factors...

- Clear objectives and guidance from CDC and other policy makers
- Clear messaging and call-to-action for the public to do their part in these times
- HCPs develop solutions that consider their patients' and communities' unique needs

Utilize the full and extended immunization season

---

**Seirus has already increased supply by more than 10% to over 55M doses**

---

**FLUAD® IMPORTANT SAFETY INFORMATION**

**INDICATIONS AND USAGE**

- FLUAD® (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for active immunization against influenza virus. It is approved for use in persons 6 years of age and older.

**CONTRAINDICATIONS**

- Hypersensitivity to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

**WARNINGS AND PRECAUTIONS**

- If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD should be based on careful consideration of the potential benefits and risks.

**ADVERSE REACTIONS**

- The most common (≥10%) systemic adverse reactions observed in clinical studies were myalgia (15%), headache (13%), and fatigue (10%).

**AS YOUR PARTNER IN PUBLIC HEALTH, THANK YOU FOR YOUR COMMITMENT AND THANKS ON THE PREVENTION OF INFLUENZA**

---

**FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted)**

**VACCINE ACTIVITIES**

- University of Queensland (CEPI) – provision of MF59® adjuvant for preclinical projects
-egg

**THERAPIES**

- Hyperimmune antibodies from convalescent plasma
- Hyperimmune antibodies from transgenic cows (human Ig gene)
- Monoclonal antibody collaborations

**Seirus & CSL are working with academia, industry and governments to develop COVID-19 vaccines and therapies**

---

**Seirus has already increased supply by more than 10% to over 55M doses**

---

**FLUAD® IMPORTANT SAFETY INFORMATION**

**INDICATIONS AND USAGE**

- FLUAD® (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for active immunization against influenza virus. It is approved for use in persons 6 years of age and older.

**CONTRAINDICATIONS**

- Hypersensitivity to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

**WARNINGS AND PRECAUTIONS**

- If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD should be based on careful consideration of the potential benefits and risks.

**ADVERSE REACTIONS**

- The most common (≥10%) systemic adverse reactions observed in clinical studies were myalgia (15%), headache (13%), and fatigue (10%). Other adverse events may occur. For a comprehensive list of local and systemic adverse reactions, please see full prescribing information.
The most common (≥10%) local and systemic reactions in adults ≥65 years of age were injection site pain (21.6%) and injection site induration (11.6%).

In children 5 through 8 years, the most commonly reported injection site adverse reactions were pain (≥50%), redness (≥10%), and swelling (≥10%).

The most common systemic adverse events were headache, myalgia, and malaise and fatigue (≥10%).

In adults 65 years of age and older, the most commonly reported injection site adverse reactions were pain and redness (≥20%).

The most common systemic adverse events were malaise and fatigue, injection site induration (13%), and change in eating habits (10%).

Immunocompromised persons may have a diminished immune response to AFLURIA QUADRIVALENT. The most common systemic adverse events were irritability (≥30%), diarrhea and loss of appetite (≥20%).

The most common local and systemic reactions in children 6 through 8 years of age were tenderness at the injection site (43%) and pain (30%).

The most common (≥10%) local and systemic reactions in children and adolescents 9 through 17 years of age were pain at the injection site (30%), headache (≥20%), and myalgia (≥10%).

In adults 18 through 64 years, the most commonly reported injection site adverse reactions were pain and redness (≥20%).

The most common systemic adverse event was myalgia (≥10%).

In children 36 through 59 months of age, the most commonly reported injection site reactions were pain (≥30%) and redness (≥10%).

The most common systemic adverse event was headache (≥20%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus USA Inc. at 1-855-358-8966 or VAERS at 1-800-822-7967 or Seqirus UK Limited or its affiliates at 0808-988-8420.